Coronaviridae

Arcturus Announces Approval of a Clinical Trial Application to Advance ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting the SARS-CoV-2 Delta Variant and Other Variants of Concern

Retrieved on: 
Monday, August 2, 2021
Infectious diseases, Health, Genetics, Pharmaceutical, Clinical trials, Coronaviridae, COVID-19 vaccines, Clinical trials, COVID-19, ARCT, Variants of SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2, SARS-CoV-2 Delta variant, Variant of concern

Titers were determined by calculating the dilution that resulted in 50% inhibition of cells expressing GFP encoded by the pseudovirus, a surrogate of virus infection.

Key Points: 
  • Titers were determined by calculating the dilution that resulted in 50% inhibition of cells expressing GFP encoded by the pseudovirus, a surrogate of virus infection.
  • We are very pleased to advance ARCT-154 into a significant, staged Phase 3 clinical development study with our partner to target SARS-CoV-2 variants of concern, including the Delta variant.
  • ARCT-154 utilizes Arcturus STARR mRNA technology, and our preclinical immunogenicity data demonstrates that our newly developed vaccine candidate elicits a strong neutralizing antibody immune response against the Delta variant and other variants of concern, said Joseph Payne, President and CEO of Arcturus.
  • Arcturus technologies are covered by its extensive patent portfolio (222 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries).

Cocrystal Pharma’s SARS-CoV-2 3CL Protease Lead CDI-45205 Demonstrates Broad-Spectrum Activity Against the SARS-CoV-2 Delta and Gamma Variants

Retrieved on: 
Thursday, July 29, 2021
Coronaviridae, Variants of SARS-CoV-2, Sarbecovirus, Zoonoses, Severe acute respiratory syndrome coronavirus 2, 3C-like protease, SARS-CoV-2 lineage B.1.617, SARS-CoV-2 Beta variant, SARS-CoV-2 Delta variant, Middle East respiratory syndrome–related coronavirus, COVID-20

BOTHELL, Wash., July 29, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) announces that its SARS-CoV-2 3CL protease lead CDI-45205 and several analogs showed potent in vitro activity against the SARS-CoV-2 Delta (India/B.1.617.2) and Gamma (Brazil/P.1) variants.

Key Points: 
  • BOTHELL, Wash., July 29, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) announces that its SARS-CoV-2 3CL protease lead CDI-45205 and several analogs showed potent in vitro activity against the SARS-CoV-2 Delta (India/B.1.617.2) and Gamma (Brazil/P.1) variants.
  • Cocrystal previously announced that CDI-45205 and analogs exhibited broad-spectrum activity against the SARS-CoV-2 Alpha (United Kingdom/B.1.1.7) and Beta (South African/B.1.351) variants, surpassing the activity observed with the Wuhan strain.
  • The broad-spectrum activity against these SARS-CoV-2 variants is highly encouraging as CDI-45205 previously demonstrated excellent in vivo efficacy in a MERS-CoV-2 infected animal model.
  • The Company continues to develop SARS-CoV-2 oral protease inhibitors and replication inhibitors using its proprietary drug discovery platform technology.

Augmenta Bioworks and TFF Pharmaceuticals Announce Positive In Vitro Data Demonstrating Binding and Neutralization of the SARS-CoV-2 Delta Variant by Lead Anti-COVID-19 Antibody, AUG-3387

Retrieved on: 
Thursday, July 29, 2021
Coronaviridae, Sarbecovirus, Zoonoses, Variants of SARS-CoV-2, COVID-19 pandemic in India, SARS-CoV-2 Delta variant, COVID-19, Variant, Delta, Severe acute respiratory syndrome coronavirus 2, Severe acute respiratory syndrome coronavirus, Severe acute respiratory syndrome

MENLO PARK, Calif. and AUSTIN, Texas, July 29, 2021 (GLOBE NEWSWIRE) -- Augmenta Bioworks, a biotechnology company enabling breakthroughs in medicine through immune profiling, and TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced positive in vitro data indicating that their lead anti-COVID-19 monoclonal antibody (“mAb”) therapy, AUG-3387, binds to and neutralizes the SARS-CoV-2 Delta variant (B.1.617.2). The Delta variant is the current dominant strain of SARS-CoV-2 in the U.S., Europe and other geographic regions around the world.

Key Points: 
  • The Delta variant is the current dominant strain of SARS-CoV-2 in the U.S., Europe and other geographic regions around the world.
  • The Delta variant now accounts for 83% of new cases in the U.S., according to recent CDC data.
  • Demonstration that AUG-3387 effectively neutralizes the Delta variant in vitro is an encouraging step towards developing the therapy to slow and prevent ongoing spread of COVID-19.
  • Those forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially.

Global Coronavirus (COVID-19) Vaccine Market to 2026 By Infection Type, Vaccine Type, Product Type, Route of Administration, Patient Type, End User, Region - ResearchAndMarkets.com

Retrieved on: 
Friday, July 30, 2021
Health, Pharmaceutical, Coronaviridae, Medicine, Health sciences, Zoonoses, COVID-19 vaccines, Sarbecovirus, Bat virome, Clinical trials, COVID-19 vaccine, Severe acute respiratory syndrome, Coronavirus, COVID-19

The "Global Coronavirus Vaccine Market, By Infection Type (SARS-CoV-2, SARS-CoV, MERS-CoV), By Vaccine Type, By Product Type, By Route of Administration, By Patient Type, By End User, By Region, Competition Forecast & Opportunities, 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Coronavirus Vaccine Market, By Infection Type (SARS-CoV-2, SARS-CoV, MERS-CoV), By Vaccine Type, By Product Type, By Route of Administration, By Patient Type, By End User, By Region, Competition Forecast & Opportunities, 2026" report has been added to ResearchAndMarkets.com's offering.
  • The Global Coronavirus Vaccine Market is expected to grow at a robust rate during the forecast period.
  • The Global Coronavirus Vaccine Market is driven by the increasing prevalence of this disease across different parts of the globe.
  • The Global Coronavirus Vaccine Market is segmented based on infection type, vaccine type, product type, route of administration, patient type, end-user, company, and region.

COVID-19 Associated With Long-Term Cognitive Dysfunction, Acceleration Of Alzheimer's Symptoms

Retrieved on: 
Thursday, July 29, 2021
Coronaviridae, Sarbecovirus, Cognitive disorders, Learning disabilities, Psychiatric diagnosis, Dementia, Alzheimer's disease, COVID-19, Severe acute respiratory syndrome coronavirus, Severe acute respiratory syndrome, Long Covid, Impact of COVID-19 on neurological, psychological and other mental health outcomes

New research reported at the Alzheimer's Association International Conference (AAIC) 2021 , held virtually and in Denver found associations between COVID-19 and persistent cognitive deficits, including the acceleration of Alzheimer's disease pathology and symptoms.

Key Points: 
  • New research reported at the Alzheimer's Association International Conference (AAIC) 2021 , held virtually and in Denver found associations between COVID-19 and persistent cognitive deficits, including the acceleration of Alzheimer's disease pathology and symptoms.
  • Of the patients, 158 were positive for SARS-CoV-2 with neurological symptoms and 152 were positive for SARS-CoV-2 without neurologic symptoms.
  • "These findings suggest that patients who had COVID-19 may have an acceleration of Alzheimer's-related symptoms and pathology," said Wisniewski.
  • Olfactory dysfunction and chronic cognitive impairment following SARS-CoV-2 infection in a sample of older adults from the Andes mountains of Argentina.

COVID-19 Associated With Long-Term Cognitive Dysfunction, Acceleration Of Alzheimer's Symptoms

Retrieved on: 
Thursday, July 29, 2021
Coronaviridae, Sarbecovirus, Cognitive disorders, Learning disabilities, Psychiatric diagnosis, Dementia, Alzheimer's disease, COVID-19, Severe acute respiratory syndrome coronavirus, Severe acute respiratory syndrome, Long Covid, Impact of COVID-19 on neurological, psychological and other mental health outcomes

New research reported at the Alzheimer's Association International Conference (AAIC) 2021 , held virtually and in Denver found associations between COVID-19 and persistent cognitive deficits, including the acceleration of Alzheimer's disease pathology and symptoms.

Key Points: 
  • New research reported at the Alzheimer's Association International Conference (AAIC) 2021 , held virtually and in Denver found associations between COVID-19 and persistent cognitive deficits, including the acceleration of Alzheimer's disease pathology and symptoms.
  • Of the patients, 158 were positive for SARS-CoV-2 with neurological symptoms and 152 were positive for SARS-CoV-2 without neurologic symptoms.
  • "These findings suggest that patients who had COVID-19 may have an acceleration of Alzheimer's-related symptoms and pathology," said Wisniewski.
  • Olfactory dysfunction and chronic cognitive impairment following SARS-CoV-2 infection in a sample of older adults from the Andes mountains of Argentina.

New Publications Confirm Paragon Genomics CleanPlex® SARS-CoV-2 Panel Enables Accurate Identification of Variants of Concern

Retrieved on: 
Wednesday, July 28, 2021
Coronaviridae, Variants of SARS-CoV-2, Sarbecovirus, COVID-19 pandemic in India, COVID-19, SARS-CoV-2 lineage B.1.617, Severe acute respiratory syndrome coronavirus 2, SARS-CoV-2 Alpha variant, SARS-CoV-2 Delta variant, Severe acute respiratory syndrome coronavirus, COVID-20

The analyses enabled the researchers to assign the viral genomes to SARS-CoV-2 lineages and confirm the presence of the B.1.1.7 variant.

Key Points: 
  • The analyses enabled the researchers to assign the viral genomes to SARS-CoV-2 lineages and confirm the presence of the B.1.1.7 variant.
  • A third study, from a Paragon Genomics public health laboratory customer, describes how the CleanPlex SARS-CoV-2 Panel enabled the early identification of one of the first confirmed cases of the B.1.617.2 Delta variant in Brazil.
  • Paragon Genomics' CleanPlex SARS-CoV-2 technology has powered variant detection and tracking since the virus first appeared.
  • In March 2020, the company launched the CleanPlex SARS-CoV-2 Panel whole genome SARS-CoV-2 sequencing on Illumina and MGI Tech sequencing platforms.

VIRALEZE SPL7013 virucidal (>99.99%) against Delta variant

Retrieved on: 
Tuesday, July 27, 2021
Coronaviridae, Sarbecovirus, Zoonoses, Biocides, Severe acute respiratory syndrome coronavirus 2, Variants of SARS-CoV-2, Antiviral drug, Virucide, COVID-19, Coronavirus, Severe acute respiratory syndrome, GC376

New antiviral testing demonstrates SPL7013, the antiviral agent in VIRALEZE nasal spray, has potent virucidal activity against the globally significant Delta variant of SARS-CoV-2, reducing infectivity of the virus by >99.99% after 30 seconds of exposure

Key Points: 
  • New antiviral testing demonstrates SPL7013, the antiviral agent in VIRALEZE nasal spray, has potent virucidal activity against the globally significant Delta variant of SARS-CoV-2, reducing infectivity of the virus by >99.99% after 30 seconds of exposure
    SPL7013, the antiviral agent in VIRALEZE, has now been shown in laboratory studies to be virucidal against all four coronavirus SARS-CoV-2 Variants of Concern: Alpha, Beta, Gamma and Delta
    These latest data further illustrate the broad-spectrum antiviral activity of SPL7013, which has been demonstrated against multiple respiratory viruses, including influenza and RSV, as well as its consistent and potent activity against multiple SARS-CoV-2 variants
    VIRALEZE antiviral nasal spray is registered for sale in Europe and India, and available in certain markets online.
  • MELBOURNE, Australia, July 27, 2021 /PRNewswire/-- Starpharma today announced new data demonstrating that SPL7013, the antiviral agent in VIRALEZE nasal spray, is active against the highly transmissible Delta variant of SARS-CoV-2, achieving more than 99.99% reduction of infectious virus in laboratory-based virucidal assays.
  • The antiviral testing of SPL7013 was conducted in the laboratory of virologist, Professor Philippe Gallay, atThe Scripps Research Institute in the US, where previous studies have also demonstrated potent antiviral and virucidal activity of SPL7013 against multiple variants of SARS-CoV-2, including the globally important Alpha, Beta and Gamma 'Variants of Concern'.
  • Percent reductions of infectious virus achieved with 10 mg/mL SPL7013 (the concentration in VIRALEZE) are shown in the table below.

Oragenics Enters into Licensing Agreement with the National Research Council of Canada, to Pursue the Rapid Development of Next-Generation SARS-CoV-2 Vaccines

Retrieved on: 
Tuesday, July 27, 2021
Biotechnology, Infectious diseases, Health, Pharmaceutical, Clinical trials, Coronaviridae, Articles, Sarbecovirus, Health, Zoonoses, Animal virology, Coronavirus, Severe acute respiratory syndrome coronavirus 2, Severe acute respiratory syndrome, Pandemic, Vaccine, COVID-19

Oragenics, Inc. (NYSE American: OGEN) today announced it has entered into a licensing agreement with the National Research Council of Canada (NRC) that will enable Oragenics to pursue the rapid development of next-generation vaccines against the SARS-CoV-2 virus and its variants.

Key Points: 
  • Oragenics, Inc. (NYSE American: OGEN) today announced it has entered into a licensing agreement with the National Research Council of Canada (NRC) that will enable Oragenics to pursue the rapid development of next-generation vaccines against the SARS-CoV-2 virus and its variants.
  • The NRC technologies, developed with support from the NRCs Pandemic Response Challenge Program, will expedite the evaluation of SARS-CoV-2 antigen candidates in preclinical and clinical studies.
  • Oragenics, Inc. is a development-stage company dedicated to fighting infectious diseases including coronaviruses and multidrug-resistant organisms.
  • Its lantibiotics program features a novel class of antibiotics against infectious diseases that have developed resistance to commercial antibiotics.

SpeeDx Launch Solution for SARS-CoV-2 Variant Analysis

Retrieved on: 
Monday, July 26, 2021
Health, Infectious diseases, Clinical trials, Research, Science, Biotechnology, Coronaviridae, Sarbecovirus, Zoonoses, Variants of SARS-CoV-2, Variant of concern, Molecular diagnostics, Severe acute respiratory syndrome coronavirus 2, Severe acute respiratory syndrome coronavirus, DiaSorin

Ltd., a developer of innovative molecular diagnostic solutions, have launched a new product line of research reagents to support reflex variant analysis for circulating SARS-CoV-2 variants of concern (VOC).

Key Points: 
  • Ltd., a developer of innovative molecular diagnostic solutions, have launched a new product line of research reagents to support reflex variant analysis for circulating SARS-CoV-2 variants of concern (VOC).
  • Founded in 2009, SpeeDx is an Australian-based private company with subsidiary offices in Austin and London, and distributors across Europe.
  • SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management.
  • For more information on SpeeDx please see: https://plexpcr.com
    SARS-CoV-2 Variant Classifications and Definitions.